Alex Philippidis / GEN - Genetic Engineering and Biotechnology News

BrainChild Bio raises $116M Series A to launch pivotal registrational trial of BCB-276 CAR T therapy for pediatric DIPG

BrainChild Bio, a Seattle Children’s spinout, raised $116 million in Series A funding to support a pivotal registrational trial of BCB-276, an autologous CAR T-cell therapy targeting DIPG in children, with plans to expand into adult CNS tumors including glioblastoma.

SSteven Brugger MMichael Jensen BBrainChild Bio WWashington Research Foundation
More: FinSMEs, Endpoints News, BioSpace, Fierce Biotech, American Chemical Society
Comments: Kyle LaHucik, Alex Philippidis
Kyle LaHucik BrainChild Bio, a Seattle Children's spinout creating CAR-T therapies for brain tumors in both children and adults, has collected $116 million to get into pivotal testing...
Alex Philippidis 8September: How does BrainChild Bio plan to stand out among drug developers targeting #cancer tumors within the CNS? Read insights from CEO Steven Brugger and founder/CSO...

No comments yet.